[go: up one dir, main page]

WO1993023035A3 - Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson - Google Patents

Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson Download PDF

Info

Publication number
WO1993023035A3
WO1993023035A3 PCT/EP1993/001099 EP9301099W WO9323035A3 WO 1993023035 A3 WO1993023035 A3 WO 1993023035A3 EP 9301099 W EP9301099 W EP 9301099W WO 9323035 A3 WO9323035 A3 WO 9323035A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
parkinson
disease
memory disorders
sexual dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1993/001099
Other languages
English (en)
Other versions
WO1993023035A2 (fr
Inventor
Robin Bradshaw Fears
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210594A external-priority patent/GB9210594D0/en
Priority claimed from GB929210576A external-priority patent/GB9210576D0/en
Priority claimed from GB929210595A external-priority patent/GB9210595D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to JP5519830A priority Critical patent/JPH07506823A/ja
Priority to EP93912699A priority patent/EP0641202A1/fr
Publication of WO1993023035A2 publication Critical patent/WO1993023035A2/fr
Publication of WO1993023035A3 publication Critical patent/WO1993023035A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agonistes de récepteurs de dopamine D3 sélectifs et leur utilisation en thérapie, inter alia, dans le traitement de troubles de la mémoire.
PCT/EP1993/001099 1992-05-18 1993-05-04 Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson Ceased WO1993023035A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5519830A JPH07506823A (ja) 1992-05-18 1993-05-04 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
EP93912699A EP0641202A1 (fr) 1992-05-18 1993-05-04 Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9210594.9 1992-05-18
GB929210594A GB9210594D0 (en) 1992-05-18 1992-05-18 Medical use
GB9210595.6 1992-05-18
GB929210576A GB9210576D0 (en) 1992-05-18 1992-05-18 Medical use
GB929210595A GB9210595D0 (en) 1992-05-18 1992-05-18 Medical use
GB9210576.6 1992-05-18

Publications (2)

Publication Number Publication Date
WO1993023035A2 WO1993023035A2 (fr) 1993-11-25
WO1993023035A3 true WO1993023035A3 (fr) 1994-03-03

Family

ID=27266192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/001099 Ceased WO1993023035A2 (fr) 1992-05-18 1993-05-04 Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson

Country Status (4)

Country Link
EP (1) EP0641202A1 (fr)
JP (1) JPH07506823A (fr)
AU (1) AU4312593A (fr)
WO (1) WO1993023035A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
ES2179362T3 (es) * 1996-08-27 2003-01-16 Wyeth Corp Derivados de 4-aminoetoxi indolona.
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AR014847A1 (es) * 1998-04-13 2001-03-28 American Home Prod 4-amino-(etilamino)-oxindoles agonistas del autoreceptor de dopamina y una composicion farmaceutica que los comprende
EP1089736A2 (fr) * 1998-06-22 2001-04-11 Queen's University At Kingston Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
CA2251255A1 (fr) * 1998-10-20 2000-04-20 Mcgill University L'utilisation d'agents dopaminergique dans le gestion de dysfonctionnement sexuel
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE602005008954D1 (de) * 2004-05-26 2008-09-25 Pfizer Indazol- und indolonderivative und deren verwendung als pharmazeutika
CN109745313A (zh) 2010-08-11 2019-05-14 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
CA2928429C (fr) 2013-10-28 2022-08-30 Drexel University Derives de phenyle aminoalkylique utiles dans le traitement du tdah et d'autres troubles cognitifs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113964A1 (fr) * 1982-12-07 1984-07-25 Smithkline Beckman Corporation 4-Aminoalkyle-2(3H)-indolones
EP0299602A2 (fr) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited L'emploi de dérivés de l'indolone pour la fabrication de médicaments pour le traitement du parkinsonisme
WO1991015513A1 (fr) * 1990-04-06 1991-10-17 Institut National De La Sante Et De La Recherche Medicale Polypeptides ayant une activite de recepteur dopaminergique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides
WO1992000735A1 (fr) * 1990-07-09 1992-01-23 Smith Kline & French Laboratories Limited Ropinirole et domperidone utilises dans la preparation d'un medicament pour le traitement de la maladie de parkinson

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113964A1 (fr) * 1982-12-07 1984-07-25 Smithkline Beckman Corporation 4-Aminoalkyle-2(3H)-indolones
EP0299602A2 (fr) * 1987-05-21 1989-01-18 Smith Kline & French Laboratories Limited L'emploi de dérivés de l'indolone pour la fabrication de médicaments pour le traitement du parkinsonisme
WO1991015513A1 (fr) * 1990-04-06 1991-10-17 Institut National De La Sante Et De La Recherche Medicale Polypeptides ayant une activite de recepteur dopaminergique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides
WO1992000735A1 (fr) * 1990-07-09 1992-01-23 Smith Kline & French Laboratories Limited Ropinirole et domperidone utilises dans la preparation d'un medicament pour le traitement de la maladie de parkinson

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AHLENIUS, S. ET AL: "EFFECTS OF PERGOLIDE AND BROMOCRIPTINE ON MALE RAT SEXUAL BEHAVIOUR", J. NEURAL TRANSMISSION, vol. 54, 1982, pages 165 - 170 *
CLOSE, S.P. ET AL: "EFFECTS OF CLASSICAL AND NOVEL AGENTS IN A MPTP-INDUCED REVERSIBLE MODEL OF PARKINSON'S DISEASE", PSYCHOPHARMACOLOGY, vol. 102, no. 3, 1990, pages 295 - 300, XP000612744, DOI: doi:10.1007/BF02244093 *
FULLER, R.W. ET AL: "PERGOLIDE: A DOPAMINE AGONIST AT BOTH D1 AND D2 RECEPTORS", LIFE SCIENCES, vol. 49, no. 13, 1991, pages 925 - 930, XP023721244, DOI: doi:10.1016/0024-3205(91)90074-L *
IZQUIERDO, I.: "DOPAMINE RECEPTORS IN THE CAUDATE NUCLEUS AND MEMORY PROCESSES", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 13, no. 1, January 1992 (1992-01-01), pages 7 - 8, XP025955002, DOI: doi:10.1016/0165-6147(92)90004-P *
KOLLER, W. ET AL: "QUINPIROLE HYDROCHLORIDE, A POTENTIAL ANTI-PARKINSONIAN DRUG", NEUROPHARMACOLOGY, vol. 26, no. 8, August 1987 (1987-08-01), pages 1031 - 1036 *
LAMBERTS, S.W. ET AL: "A COMPARISON OF THE EFFICACY AND SAFETY OF PERGOLIDE AND BROMOCRIPTINE IN THE TREATMENT OF HYPERPROLACTINAEMIA", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 72, no. 3, March 1991 (1991-03-01), pages 635 - 641 *
MCGURK, S.R. ET AL: "DOPAMINERGIC DRUGS REVERSE THE IMPAIRMENT OF RADIAL-ARM MAZE PERFORMANCE CAUSED BY LESIONS INVOLVING THE CHOLINERGIC MEDIAL PATHWAY", NEUROSCIENCE, vol. 50, no. 1, 1992, pages 129 - 135, XP024385904, DOI: doi:10.1016/0306-4522(92)90387-H *
MUSCAT, R. ET AL: "ANTIDEPRESSANT-LIKE EFFECTS OF DOPAMINE AGONISTS IN AN ANIMAL MODEL OF DEPRESSION", BIOLOGICAL PSYCHIATRY, vol. 31, no. 9, 1 May 1991 (1991-05-01), pages 937 - 946, XP024250874, DOI: doi:10.1016/0006-3223(92)90119-K *
PACKARD, M.G. ET AL: "DISSOCIATION OF HIPPOCAMPUS AND CAUDATE NUCLEUS MEMORY SYSTEMS BY POSTTRAINING INTRACEREBRAL INJECTION OF DOPAMINE AGONISTS", BEHAVIOURAL NEUROSCIENCE, vol. 105, no. 2, April 1991 (1991-04-01), pages 295 - 306 *
PACKARD, M.G. ET AL: "MEMORY FACILITATION PRODUCED BY DOPAMINE AGONISTS: ROLE OF RECEPTOR SUBTYPE AND MNEMONIC REQUIREMENTS", PHARMACOLOGY BIOCHEMISTRY & BEHAVIOUR, vol. 33, no. 3, 1989, pages 511 - 518, XP025851515, DOI: doi:10.1016/0091-3057(89)90378-X *
POMERANTZ, S.M.: "QUINEROLANE (LY163502), A D2 DOPAMINE RECEPTOR AGONIST, ACTS CENTRALLY TO FACILITATE PENILE ERECTIONS OF MALE RHESUS MONKEYS", PHARMACOLOGY BIOCHEMISTRY & BEHAVIOUR, vol. 39, no. 1, 1991, pages 123 - 128, XP023808720, DOI: doi:10.1016/0091-3057(91)90408-T *
SOKOLOFF, P. ET AL: "PHARMACOLOGY OF HUMAN DOPAMINE D3 RECEPTOR EXPRESSED IN A MAMMALIAN CELL LINE: COMPARISON WITH D2 RECEPTOR", EUROPEAN JOURNAL OF PHARMACOLOGY, MOLECULAR PHARMACOLOGY SECTION, vol. 225, no. 4, 1992, pages 331 - 337, XP023861743, DOI: doi:10.1016/0922-4106(92)90107-7 *
SOKOLOFF, PIERRE ET AL: "LOCALIZATION AND FUNCTION OF THE DOPAMINE D3 RECEPTOR", ARZNEIMITTEL FORSCHUNG, vol. 42(I), no. 2A, February 1992 (1992-02-01), pages 224 - 230 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients

Also Published As

Publication number Publication date
WO1993023035A2 (fr) 1993-11-25
JPH07506823A (ja) 1995-07-27
EP0641202A1 (fr) 1995-03-08
AU4312593A (en) 1993-12-13

Similar Documents

Publication Publication Date Title
WO1993023035A3 (fr) Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
WO1994004120A3 (fr) Methode de traitement de defaillances sexuelles chez l'animal et chez l'homme au moyen d'un agonsite de h
CA2269698A1 (fr) Agent therapeutique contre les troubles neurodegeneratifs
CA2264895A1 (fr) Dispositif et methode de traitement de maladies ophtalmiques
EP0859637A4 (fr) Compositions destinees au traitement et au diagnostic des problemes de poids, dont l'obesite
KR100246065B1 (en) Substituted 3-aminoquinuclidines
IS7747A (is) Spíról[1-asabísýkló[2.2.2]oktan-3,2'(3'H)-fúró[2,3-b]pýridín] til að nota við að meðhöndla geðtruflanir og sjúkdóma sem skerða vitsmuni
BG104476A (en) Therapeutical form for tolterodin with controlled release
EP1027011A4 (fr) Administration d'agents actifs, notamment d'agonistes et antagonistes du recepteur de 5-ht, afin de traiter l'ejaculation precoce
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2000012623A3 (fr) Utilisation
HU9502063D0 (en) Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes
AU3537893A (en) Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use
NZ509762A (en) 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
CA2347863A1 (fr) Traitement des affections de la retine
AU3987593A (en) The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
NO984572D0 (no) Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e
WO1992015304A3 (fr) Agonistes des recepteurs kappa pour le traitement de l'ischemie cerebrale
AU4856600A (en) Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
AU2110095A (en) Glucosidic derivatives of n-acyl alkylamines exerting neuroprotective, neurotrophic and anti-inflammatory action, useful in acute and chronic disorders of the central nervous system connected with excitotoxicity
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
CA2197176A1 (fr) Utilisation de selegiline dans le traitement de l'epilepsie
EP0666745A4 (fr) Procedes de diagnostic et de traitement de la maladie de parkinson.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993912699

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 338497

Date of ref document: 19941130

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1993912699

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993912699

Country of ref document: EP